Change of erythrocyte sedimentation rate as prognostic biomarker for Mycobacterium avium complex pulmonary disease through anti-mycobacterial treatment.

IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Therapeutic Advances in Respiratory Disease Pub Date : 2024-01-01 DOI:10.1177/17534666241282272
Hyeontaek Hwang, Joong-Yub Kim, Jae-Joon Yim, Nakwon Kwak
{"title":"Change of erythrocyte sedimentation rate as prognostic biomarker for <i>Mycobacterium avium</i> complex pulmonary disease through anti-mycobacterial treatment.","authors":"Hyeontaek Hwang, Joong-Yub Kim, Jae-Joon Yim, Nakwon Kwak","doi":"10.1177/17534666241282272","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It remains unclear whether erythrocyte sedimentation rate (ESR) accurately predicts prognosis during treatment and how ESR changes.</p><p><strong>Objectives: </strong>We aimed to assess the predictive values of ESR as a prognostic factor of <i>Mycobacterium avium</i> complex pulmonary disease (MAC-PD) while on anti-mycobacterial treatment and its changes according to the treatment responses.</p><p><strong>Design: </strong>This study is a retrospective cohort study.</p><p><strong>Methods: </strong>This study included patients aged 18 years or older who initiated anti-mycobacterial treatment for MAC-PD at Seoul National University Hospital between January 1, 2009 and March 31, 2022. ESR should be measured at least twice, with a minimum interval of 3 months, during the initial 12 months from the commencement of antibiotic treatment. A mixed linear regression and Cox proportional-hazards models were used to analyze repeated ESR data and the association with patient survival.</p><p><strong>Results: </strong>Of a total of 825 patients who initiated antibiotic treatment for MAC-PD, 369 patients were included in the analysis. Increased levels of ESR during the treatment process were associated with a higher risk of mortality (adjusted hazard ratio 1.03; 95% confidence interval, 1.02-1.03) after adjusting age, sex, comorbidities, presence of cavity, acid-fast bacilli smear positivity, and culture conversion at 12 months. During the treatment, ESR at 12 months of treatment significantly decreased compared to baseline ESR in both the culture-converted and not-converted groups, which was categorized based on whether the culture conversion was achieved within the 12 months after treatment initiation.</p><p><strong>Conclusion: </strong>ESR predicted mortality during treatment and decreased over time, regardless of treatment outcomes. Our results underscore the importance of administering anti-mycobacterial treatment even in patients who did not achieve a microbiological cure.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241282272"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421399/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Respiratory Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17534666241282272","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It remains unclear whether erythrocyte sedimentation rate (ESR) accurately predicts prognosis during treatment and how ESR changes.

Objectives: We aimed to assess the predictive values of ESR as a prognostic factor of Mycobacterium avium complex pulmonary disease (MAC-PD) while on anti-mycobacterial treatment and its changes according to the treatment responses.

Design: This study is a retrospective cohort study.

Methods: This study included patients aged 18 years or older who initiated anti-mycobacterial treatment for MAC-PD at Seoul National University Hospital between January 1, 2009 and March 31, 2022. ESR should be measured at least twice, with a minimum interval of 3 months, during the initial 12 months from the commencement of antibiotic treatment. A mixed linear regression and Cox proportional-hazards models were used to analyze repeated ESR data and the association with patient survival.

Results: Of a total of 825 patients who initiated antibiotic treatment for MAC-PD, 369 patients were included in the analysis. Increased levels of ESR during the treatment process were associated with a higher risk of mortality (adjusted hazard ratio 1.03; 95% confidence interval, 1.02-1.03) after adjusting age, sex, comorbidities, presence of cavity, acid-fast bacilli smear positivity, and culture conversion at 12 months. During the treatment, ESR at 12 months of treatment significantly decreased compared to baseline ESR in both the culture-converted and not-converted groups, which was categorized based on whether the culture conversion was achieved within the 12 months after treatment initiation.

Conclusion: ESR predicted mortality during treatment and decreased over time, regardless of treatment outcomes. Our results underscore the importance of administering anti-mycobacterial treatment even in patients who did not achieve a microbiological cure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
红细胞沉降率的变化作为复合分枝杆菌肺病抗分枝杆菌治疗的预后生物标志物。
背景:目前尚不清楚红细胞沉降率(ESR)是否能准确预测治疗期间的预后,也不清楚ESR是如何变化的:我们旨在评估血沉作为抗分枝杆菌治疗期间复合分枝杆菌肺病(MAC-PD)预后因素的预测价值,以及血沉随治疗反应的变化情况:本研究是一项回顾性队列研究:本研究包括 2009 年 1 月 1 日至 2022 年 3 月 31 日期间在首尔大学医院开始接受 MAC-PD 抗霉菌治疗的 18 岁或以上患者。在抗生素治疗开始后的最初 12 个月内,应至少测量两次血沉,每次间隔至少 3 个月。采用混合线性回归和 Cox 比例危险模型分析重复的血沉数据以及与患者生存率的关系:在825名开始接受抗生素治疗的MAC-PD患者中,有369名患者纳入了分析。在调整了年龄、性别、合并症、是否存在空洞、酸性ast杆菌涂片阳性和12个月培养转换率后,治疗过程中ESR水平的升高与较高的死亡风险相关(调整后危险比为1.03;95%置信区间为1.02-1.03)。在治疗期间,与基线血沉相比,培养转阴组和未转阴组治疗12个月时的血沉均显著下降:结论:无论治疗结果如何,ESR都能预测治疗期间的死亡率,并随着时间的推移而降低。我们的研究结果表明,即使患者没有获得微生物学治愈,也必须进行抗霉菌治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
57
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.
期刊最新文献
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT). Association between albumin corrected anion gap and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease. Sleep and breathing in children with Joubert syndrome and a review of other rare congenital hindbrain malformations. The impact of quantitative platform on candidacy for bronchoscopic lung volume reduction: a multi-center retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1